+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
Global Auranofin Market by Form (Capsule, Tablet), Indication (Seronegative Rheumatoid Arthritis, Seropositive Rheumatoid Arthritis) - Forecast 2024-2030- Product Image
Global Auranofin Market by Form (Capsule, Tablet), Indication (Seronegative Rheumatoid Arthritis, Seropositive Rheumatoid Arthritis) - Forecast 2024-2030- Product Image
Sale

Global Auranofin Market by Form (Capsule, Tablet), Indication (Seronegative Rheumatoid Arthritis, Seropositive Rheumatoid Arthritis) - Forecast 2024-2030

  • PDF Icon

    Report

  • 191 Pages
  • May 2024
  • Region: Global
  • 360iResearch™
  • ID: 5967856
UP TO OFF until Dec 31st 2024
1h Free Analyst Time
Description Jump to:
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.
The Auranofin Market size was estimated at USD 209.20 million in 2023, USD 218.99 million in 2024, and is expected to grow at a CAGR of 4.81% to reach USD 290.85 million by 2030.

Auranofin is a gold-containing, orally administered compound classified as a disease-modifying antirheumatic drug (DMARD). It was specifically designed for the treatment of rheumatoid arthritis, a chronic autoimmune situation characterized by inflammation and pain in the joints. Auranofin works by modulating the immune system to decrease inflammation and slows the progression of the disease. Additionally, its immunoregulatory properties have spurred research into its potential efficacy against other autoimmune disorders and certain types of cancer.

Despite its therapeutic benefits, its use is often carefully weighed against potential side effects, including renal and hepatic impairment, necessitating regular monitoring of patients under treatment. Auranofin represents a unique approach to managing autoimmune diseases, emphasizing the importance of balancing efficacy with safety in chronic disease management. The rising prevalence of rheumatoid arthritis and the need for alternative treatments amidst growing drug resistance are fundamental growth drivers. Advances in research demonstrating auranofin's efficacy against certain cancers and parasites further expand its market. Moreover, governmental and non-governmental funding for chronic diseases and cancer research plays a significant role in market expansion. However, side effects associated with auranofin, such as gastrointestinal issues and dermatological reactions, limit its acceptability among some patients. Regulatory hurdles and the high cost of clinical trials for new applications are significant challenges. The exploration of Auranofin's application in oncology and parasitology presents significant growth opportunities. Its potential effectiveness against drug-resistant cancers and parasites could open new market segments. Additionally, partnerships between pharmaceutical companies and research institutions aimed at expanding Auranofin's applications could spur further growth.

Regional Insights

In the Americas, particularly in the United States and Canada, the market for auranofin has been driven by its prolonged use in treating chronic rheumatoid arthritis. The market is mature with a stable demand, largely due to the established healthcare infrastructure and reimbursement policies favoring the drug's prescription. However, growing competition from newer biologic DMARDs and biosimilars poses challenges to its market share. In Europe, the market is highly regulated with a strong emphasis on cost-effectiveness and clinical outcomes, which could limit the growth potential of Auranofin despite its proven efficacy. The Middle East, while smaller in market size, shows promise due to growing healthcare infrastructure and investment.

The Asia Pacific region is anticipated to depict significant growth for the auranofin market due to rapidly evolving healthcare systems, increasing patient awareness, and growing prevalence of rheumatoid arthritis. Countries including China and India, with their vast populations and improving healthcare settings, are expected to contribute substantially to the market. Furthermore, the region's increasing research and development activities may offer new opportunities for Auranofin in alternative therapeutic applications.

Market Trends by Segment

  • Form: Suitability of auranofin capsules to provide a systemic delivery of the active drug, ensuring a uniform distribution
  • Indication: Preference for auranofin in managing seropositive RA owing to its cellular mechanisms involved in inflammation

Industry Insights

  • Market Dynamics
  • Market Disruption Analysis
  • Porter’s Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis
  • FPNV Positioning Matrix
  • Market Share Analysis
  • Strategy Analysis and Recommendations

Recent Developments

Arthritis Foundation Invests USD 1.1 Million in Refractory Rheumatoid Arthritis Research

The Arthritis Foundation has committed USD 1.1 million to investigate refractory rheumatoid arthritis (RA), a condition that eludes current treatment modalities, impacting the lives of a million individuals living with RA in the U.S. This investment aims to uncover novel biomarkers, therapeutic targets, and understanding patients' divergent immune system responses, thereby paving the way for personalized treatment strategies. Such initiatives resonate with the Foundation's mission to advance scientific discovery in RA and ensure the inclusivity of diverse populations throughout the research.

Key Company Profiles

The report delves into recent significant developments in the Auranofin Market, highlighting leading vendors and their innovative profiles. These include Chugai Pharmaceutical Co Ltd, LGM Pharma, Prometheus Laboratories Inc., Sebela Pharmaceuticals Inc., Taj Pharmaceuticals Limited, and Xediton Pharmaceuticals.

This research report offers invaluable insights into various crucial aspects of the Auranofin Market:

  1. Market Penetration: This section thoroughly overviews the current market landscape, incorporating detailed data from key industry players.
  2. Market Development: The report examines potential growth prospects in emerging markets and assesses expansion opportunities in mature segments.
  3. Market Diversification: This includes detailed information on recent product launches, untapped geographic regions, recent industry developments, and strategic investments.
  4. Competitive Assessment & Intelligence: An in-depth analysis of the competitive landscape is conducted, covering market share, strategic approaches, product range, certifications, regulatory approvals, patent analysis, technology developments, and advancements in the manufacturing capabilities of leading market players.
  5. Product Development & Innovation: This section offers insights into upcoming technologies, research and development efforts, and notable advancements in product innovation.

Additionally, the report addresses key questions to assist stakeholders in making informed decisions:

  1. What is the current market size and projected growth?
  2. Which products, segments, applications, and regions offer promising investment opportunities?
  3. What are the prevailing technology trends and regulatory frameworks?
  4. What is the market share and positioning of the leading vendors?
  5. What revenue sources and strategic opportunities do vendors in the market consider when deciding to enter or exit?

Table of Contents

1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Rising prevalence of rheumatoid arthritis and the need for alternative treatments
5.1.1.2. Auranofin’s potential against parasitic infections, certain cancers, and as an antiviral agent.
5.1.1.3. Governmental and non-governmental funding for chronic diseases and cancer research
5.1.2. Restraints
5.1.2.1. Side effects associated with Auranofin
5.1.3. Opportunities
5.1.3.1. Exploring auranofin's efficacy in new therapeutic applications
5.1.3.2. Partnerships between pharmaceutical companies and research institutions
5.1.4. Challenges
5.1.4.1. Complex regulatory landscape and the high cost of clinical trials
5.2. Market Segmentation Analysis
5.2.1. Form: Suitability of auranofin capsules to provide a systemic delivery of the active drug, ensuring a uniform distribution
5.2.2. Indication: Preference for auranofin in managing seropositive RA owing to its cellular mechanisms involved in inflammation.
5.3. Market Disruption Analysis
5.4. Porter’s Five Forces Analysis
5.4.1. Threat of New Entrants
5.4.2. Threat of Substitutes
5.4.3. Bargaining Power of Customers
5.4.4. Bargaining Power of Suppliers
5.4.5. Industry Rivalry
5.5. Value Chain & Critical Path Analysis
5.6. Pricing Analysis
5.7. Technology Analysis
5.8. Patent Analysis
5.9. Trade Analysis
5.10. Regulatory Framework Analysis
6. Auranofin Market, by Form
6.1. Introduction
6.2. Capsule
6.3. Tablet
7. Auranofin Market, by Indication
7.1. Introduction
7.2. Seronegative Rheumatoid Arthritis
7.3. Seropositive Rheumatoid Arthritis
8. Americas Auranofin Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Auranofin Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Auranofin Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. Market Share Analysis, 2023
11.2. FPNV Positioning Matrix, 2023
11.3. Competitive Scenario Analysis
11.3.1. Arthritis Foundation Invests USD 1.1 Million in Refractory Rheumatoid Arthritis Research
11.4. Strategy Analysis & Recommendation
12. Competitive Portfolio
12.1. Key Company Profiles
12.2. Key Product Portfolio
List of Figures
FIGURE 1. AURANOFIN MARKET RESEARCH PROCESS
FIGURE 2. AURANOFIN MARKET SIZE, 2023 VS 2030
FIGURE 3. GLOBAL AURANOFIN MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2023 VS 2030 (%)
FIGURE 5. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 6. AURANOFIN MARKET DYNAMICS
FIGURE 7. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2023 VS 2030 (%)
FIGURE 8. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 9. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2023 VS 2030 (%)
FIGURE 10. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 11. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 12. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 13. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2023 VS 2030 (%)
FIGURE 14. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 15. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 16. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 17. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
FIGURE 18. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
FIGURE 19. AURANOFIN MARKET SHARE, BY KEY PLAYER, 2023
FIGURE 20. AURANOFIN MARKET, FPNV POSITIONING MATRIX, 2023
List of Tables
TABLE 1. AURANOFIN MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
TABLE 3. GLOBAL AURANOFIN MARKET SIZE, 2018-2023 (USD MILLION)
TABLE 4. GLOBAL AURANOFIN MARKET SIZE, 2024-2030 (USD MILLION)
TABLE 5. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
TABLE 6. GLOBAL AURANOFIN MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
TABLE 7. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 8. GLOBAL AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 9. GLOBAL AURANOFIN MARKET SIZE, BY CAPSULE, BY REGION, 2018-2023 (USD MILLION)
TABLE 10. GLOBAL AURANOFIN MARKET SIZE, BY CAPSULE, BY REGION, 2024-2030 (USD MILLION)
TABLE 11. GLOBAL AURANOFIN MARKET SIZE, BY TABLET, BY REGION, 2018-2023 (USD MILLION)
TABLE 12. GLOBAL AURANOFIN MARKET SIZE, BY TABLET, BY REGION, 2024-2030 (USD MILLION)
TABLE 13. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 14. GLOBAL AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 15. GLOBAL AURANOFIN MARKET SIZE, BY SERONEGATIVE RHEUMATOID ARTHRITIS, BY REGION, 2018-2023 (USD MILLION)
TABLE 16. GLOBAL AURANOFIN MARKET SIZE, BY SERONEGATIVE RHEUMATOID ARTHRITIS, BY REGION, 2024-2030 (USD MILLION)
TABLE 17. GLOBAL AURANOFIN MARKET SIZE, BY SEROPOSITIVE RHEUMATOID ARTHRITIS, BY REGION, 2018-2023 (USD MILLION)
TABLE 18. GLOBAL AURANOFIN MARKET SIZE, BY SEROPOSITIVE RHEUMATOID ARTHRITIS, BY REGION, 2024-2030 (USD MILLION)
TABLE 19. AMERICAS AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 20. AMERICAS AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 21. AMERICAS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 22. AMERICAS AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 23. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 24. AMERICAS AURANOFIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 25. ARGENTINA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 26. ARGENTINA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 27. ARGENTINA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 28. ARGENTINA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 29. BRAZIL AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 30. BRAZIL AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 31. BRAZIL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 32. BRAZIL AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 33. CANADA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 34. CANADA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 35. CANADA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 36. CANADA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 37. MEXICO AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 38. MEXICO AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 39. MEXICO AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 40. MEXICO AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 41. UNITED STATES AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 42. UNITED STATES AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 43. UNITED STATES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 44. UNITED STATES AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 45. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
TABLE 46. UNITED STATES AURANOFIN MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
TABLE 47. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 48. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 49. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 50. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 51. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 52. ASIA-PACIFIC AURANOFIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 53. AUSTRALIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 54. AUSTRALIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 55. AUSTRALIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 56. AUSTRALIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 57. CHINA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 58. CHINA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 59. CHINA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 60. CHINA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 61. INDIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 62. INDIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 63. INDIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 64. INDIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 65. INDONESIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 66. INDONESIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 67. INDONESIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 68. INDONESIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 69. JAPAN AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 70. JAPAN AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 71. JAPAN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 72. JAPAN AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 73. MALAYSIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 74. MALAYSIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 75. MALAYSIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 76. MALAYSIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 77. PHILIPPINES AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 78. PHILIPPINES AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 79. PHILIPPINES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 80. PHILIPPINES AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 81. SINGAPORE AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 82. SINGAPORE AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 83. SINGAPORE AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 84. SINGAPORE AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 85. SOUTH KOREA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 86. SOUTH KOREA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 87. SOUTH KOREA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 88. SOUTH KOREA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 89. TAIWAN AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 90. TAIWAN AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 91. TAIWAN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 92. TAIWAN AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 93. THAILAND AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 94. THAILAND AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 95. THAILAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 96. THAILAND AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 97. VIETNAM AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 98. VIETNAM AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 99. VIETNAM AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 100. VIETNAM AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 101. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 102. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 103. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 104. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 105. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
TABLE 106. EUROPE, MIDDLE EAST & AFRICA AURANOFIN MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
TABLE 107. DENMARK AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 108. DENMARK AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 109. DENMARK AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 110. DENMARK AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 111. EGYPT AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 112. EGYPT AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 113. EGYPT AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 114. EGYPT AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 115. FINLAND AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 116. FINLAND AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 117. FINLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 118. FINLAND AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 119. FRANCE AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 120. FRANCE AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 121. FRANCE AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 122. FRANCE AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 123. GERMANY AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 124. GERMANY AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 125. GERMANY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 126. GERMANY AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 127. ISRAEL AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 128. ISRAEL AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 129. ISRAEL AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 130. ISRAEL AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 131. ITALY AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 132. ITALY AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 133. ITALY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 134. ITALY AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 135. NETHERLANDS AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 136. NETHERLANDS AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 137. NETHERLANDS AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 138. NETHERLANDS AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 139. NIGERIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 140. NIGERIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 141. NIGERIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 142. NIGERIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 143. NORWAY AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 144. NORWAY AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 145. NORWAY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 146. NORWAY AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 147. POLAND AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 148. POLAND AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 149. POLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 150. POLAND AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 151. QATAR AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 152. QATAR AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 153. QATAR AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 154. QATAR AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 155. RUSSIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 156. RUSSIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 157. RUSSIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 158. RUSSIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 159. SAUDI ARABIA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 160. SAUDI ARABIA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 161. SAUDI ARABIA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 162. SAUDI ARABIA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 163. SOUTH AFRICA AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 164. SOUTH AFRICA AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 165. SOUTH AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 166. SOUTH AFRICA AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 167. SPAIN AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 168. SPAIN AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 169. SPAIN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 170. SPAIN AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 171. SWEDEN AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 172. SWEDEN AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 173. SWEDEN AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 174. SWEDEN AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 175. SWITZERLAND AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 176. SWITZERLAND AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 177. SWITZERLAND AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 178. SWITZERLAND AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 179. TURKEY AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 180. TURKEY AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 181. TURKEY AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 182. TURKEY AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 183. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 184. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 185. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 186. UNITED ARAB EMIRATES AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 187. UNITED KINGDOM AURANOFIN MARKET SIZE, BY FORM, 2018-2023 (USD MILLION)
TABLE 188. UNITED KINGDOM AURANOFIN MARKET SIZE, BY FORM, 2024-2030 (USD MILLION)
TABLE 189. UNITED KINGDOM AURANOFIN MARKET SIZE, BY INDICATION, 2018-2023 (USD MILLION)
TABLE 190. UNITED KINGDOM AURANOFIN MARKET SIZE, BY INDICATION, 2024-2030 (USD MILLION)
TABLE 191. AURANOFIN MARKET SHARE, BY KEY PLAYER, 2023
TABLE 192. AURANOFIN MARKET, FPNV POSITIONING MATRIX, 2023

Companies Mentioned

  • Chugai Pharmaceutical Co Ltd
  • LGM Pharma
  • Prometheus Laboratories Inc.
  • Sebela Pharmaceuticals Inc.
  • Taj Pharmaceuticals Limited
  • Xediton Pharmaceuticals

Methodology

Loading
LOADING...

Table Information

Report AttributeDetails
No. of Pages191
PublishedMay 2024
Forecast Period2024 - 2030
Estimated Market Value ( USD ) in 2024 $ 218.99 Million
Forecasted Market Value ( USD ) by 2030 $ 290.85 Million
Compound Annual Growth Rate4.8%
Regions CoveredGlobal
No. of Companies Mentioned6

Related Topics

Related Reports

Auranofin (CAS 34031-32-8) Global Market Research Report 2024 - Product Image

Auranofin (CAS 34031-32-8) Global Market Research Report 2024

  • Report
  • 50 Pages
  • Global
From
Global Collagen Vascular Diseases Market by Product (Diagnosis, Treatments), Indication (Ankylosing Spondylitis, Dermatomyositis, Polyarteritis Nodosa), End-Use - Forecast 2024-2030 - Product Image

Global Collagen Vascular Diseases Market by Product (Diagnosis, Treatments), Indication (Ankylosing Spondylitis, Dermatomyositis, Polyarteritis Nodosa), End-Use - Forecast 2024-2030

  • Report
  • 188 Pages
  • Global
From
Global Rheumatology Therapeutics Market by Indication (Ankylosing Spondylitis, Gout, Osteoarthritis), Distribution Channel (Offline Mode, Online Stores) - Forecast 2024-2030 - Product Image

Global Rheumatology Therapeutics Market by Indication (Ankylosing Spondylitis, Gout, Osteoarthritis), Distribution Channel (Offline Mode, Online Stores) - Forecast 2024-2030

  • Report
  • 184 Pages
  • Global
From
Bispecific Antibodies Market Size, Share & Trends Analysis Report By Indication (Cancer, Inflammatory & Autoimmune disorders), By Region (North America, Europe, Asia Pacific), And Segment Forecasts, 2023-2030 - Product Image

Bispecific Antibodies Market Size, Share & Trends Analysis Report By Indication (Cancer, Inflammatory & Autoimmune disorders), By Region (North America, Europe, Asia Pacific), And Segment Forecasts, 2023-2030

  • Report
  • 120 Pages
  • Global
From
Sjogren's Syndrome - Market Insight, Epidemiology and Market Forecast - 2034 - Product Image

Sjogren's Syndrome - Market Insight, Epidemiology and Market Forecast - 2034

  • Drug Pipelines
  • 202 Pages
  • Global
From

About the Market

Auranofin is a drug used to treat immune disorders, such as rheumatoid arthritis, psoriatic arthritis, and ankylosing spondylitis. It is an oral gold-based medication that works by suppressing the immune system and reducing inflammation. Auranofin is a relatively new drug, having been approved by the FDA in 1985. It is generally well-tolerated, with few side effects. Auranofin is used in combination with other medications to treat immune disorders. It is often prescribed in combination with non-steroidal anti-inflammatory drugs (NSAIDs) and disease-modifying antirheumatic drugs (DMARDs). Auranofin is also used to treat other conditions, such as lupus and Sjogren's syndrome. The Auranofin market is a growing one, with many companies offering the drug. Some of the companies in the market include Mylan, Teva Pharmaceuticals, and Sandoz. Other companies, such as Pfizer, Merck, and Novartis, also offer Auranofin in some countries. Show Less Read more

Copyright © 2002-2024 Research and Markets. All Rights Reserved.